Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue of $450K in Q2 FY2026

Q2 FY2026 revenue was $450K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$450K— QoQ
Last fiscal yearDec 2025
$1.35M— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
1.35M USD
Year-over-year change
—

Revenue vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
ATTO Competitors
Revenue for ATTO and competitors
Company Period LTM YoY 3-year CAGR
ANABAnaptysBio, Inc.LTM Mar 2026$232.39M USD+107.7%+183.6%
QTTBQ32 Bio Inc.LTM Mar 2026$53.74M USD—+100.7%
EVMNEvommune, Inc.LTM Mar 2026$10M USD——
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$8.37M USD-52.9%-35.9%
ALMSAlumis Inc. Common StockLTM Jun 2026$7.4M USD-63.1%—
ATTOAttovia Therapeutics, Inc.FY2025$1.35M USD——
CNTBConnect Biopharma Holdings LimitedFY2025$64K USD-99.8%—
ORKAOruka Therapeutics, Inc.LTM Sep 2026$0 USD——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$0 USD——
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY2024€0 EUR——
ZURAZura Bio LimitedLTM Mar 2026$0 USD——
Peer median (excluding ATTO) —-58.0%+100.7%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2024
Dec 2024
FY2025
Dec 2025
Revenue01.35M
Cost of Revenue313K804K
Gross Profit(313K)546K
Gross Margin—40.4%
Research & Development33.86M54.15M
Selling, General & Admin7.38M13.55M
Operating Expenses41.24M67.71M
Depreciation & Amortization313K804K
EBITDA(41.24M)(66.36M)
EBITDA Margin—-4915.2%
Operating Income(41.55M)(67.16M)
Operating Margin—-4974.7%
Interest Income3.44M6.63M
Interest Expense00
Other Income / Expenses1.75M6.53M
Income Before Tax(39.8M)(60.63M)
Pre-Tax Margin—-4490.9%
Income Tax Expense00
Net Income(39.8M)(60.63M)
Net Margin—-4490.9%
EPS (Basic)(1.05)(1.42)
EPS (Diluted)(1.05)(1.42)
Weighted Avg Shares43.03M43.03M
Weighted Avg Shares (Diluted)43.03M43.03M

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.